1 In adults with obesity, along with diet and exercise, A well-studied safety profile for adults with obesity: Pooled safety data from 2 weight-management clinical trials evaluating Wegovy HD 7.2 mg 1 Wegovy HD (semaglutide) injection 7.2 mg had a safety profile consistent with Wegovy 2.4 mg 1,3 5% of patients with Wegovy HD 7.2 mg pen, 5% of patients with Wegovy 2.4 mg pen, and 2% of patients with placebo permanently discontinued as a result of adverse reactions 1 The most common adverse reactions leading to discontinuation were gastrointestinal disorders: 3% of patients with Wegovy HD 7.2 mg pen, 3% of patients with Wegovy 2.4 mg pen, and 0.3% of patients with placebo 1 Includes allodynia, burning sensation, dysesthesia, hyperesthesia, hyperpathia, pain of skin, paresthesia, sensitive skin, skin burning sensation, skin discomfort, and skin sensitization

CrossRef Socioeconomic Factors Impact the Perception of Healthcare Experiences in Patients with Cirrhosis Nicole Ng, Subhanik Purkayastha, Xiaohan Ying, Arun Jesudian, Russell Rosenblatt Digestive Diseases and Sciences .2026
Demirta H, zer A, Yldrm AK, Dursun AD, Sezen C, Arslan M
Several states have independently expanded coverage in 2024 and 2025, and advocacy organizations continue to push for universal Medicaid coverage of weight loss shots
Pro tip: always stir it well in at least 8 ounces of water (for a single dose) or 16 oz of water (for a double dose)
Storage method: Store at a temperature not exceeding 30 degrees